Skip to main content

This website is intended exclusively for healthcare professionals residing and/or working in the KSA.

Sanofi branded clouded background image

Latest Articles

The ATOS Study: Real-World Study on Effectiveness of Insulin Glargine U300 in the Gulf Region.

The ATOS Study: Real-World Study on Effectiveness of Insulin Glargine U300 in the Gulf Region.

SoliD: Redefine Treatment Paradigm Post-OAD

Need to redefine the treatment paradigm Post OAD

Need to redefine the treatment paradigm Post OAD

Inside Diabetes: ATTD Edition | Type 2 Diabetes

Inside Diabetes: ATTD Edition | Type 2 Diabetes

Inside Diabetes: ATTD Edition | Type 1 Diabetes

Inside Diabetes: ATTD Edition | Type 1 Diabetes

How to screen for Autoimmune T1D

How to screen for Autoimmune T1D

Groundbreaking SoliD Study: Comparative Efficacy of iGlarLixi and IDegAsp

A narrative review for clinicians on insulin management for Type 2 Diabetes during Ramadan

A narrative review for clinicians on insulin management for Type 2 Diabetes during Ramadan

Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes- Clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial.

Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: Clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial.